{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:21:20Z","timestamp":1771921280217,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04478-7","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:24:22Z","timestamp":1763979862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Marc","family":"Elias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charbel","family":"Yazbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Zaarour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Sleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8800-2796","authenticated-orcid":false,"given":"Georges","family":"Raad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Akiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"4478_CR1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.073","author":"TL Cover","year":"2009","unstructured":"Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.073.","journal-title":"Gastroenterology"},{"key":"4478_CR2","doi-asserted-by":"crossref","unstructured":"Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20.","DOI":"10.3748\/wjg.v20.i36.12781"},{"key":"4478_CR3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i27.4867","author":"VI Reshetnyak","year":"2017","unstructured":"Reshetnyak VI, Reshetnyak TM. Significance of dormant forms of Helicobacter pylori in ulcerogenesis. World J Gastroenterol. 2017. https:\/\/doi.org\/10.3748\/wjg.v23.i27.4867.","journal-title":"World J Gastroenterol"},{"key":"4478_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","author":"RWM Van Der Hulst","year":"1996","unstructured":"Van Der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996. https:\/\/doi.org\/10.1111\/j.1523-5378.1996.tb00003.x.","journal-title":"Helicobacter"},{"key":"4478_CR5","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, Gisbert JP, Kuipers EJ, Axon A, et al. Management of helicobacter pylori infection-the Maastricht V\/Florence consensus report. Gut. 2017;66.","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"4478_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1293649","author":"SM Jung","year":"2016","unstructured":"Jung SM, Cheung DY, Kim J Il, Kim I, Seong H. Comparing the efficacy of concomitant therapy with sequential therapy as the first-line therapy of Helicobacter pylori eradication. Gastroenterol Res Pract. 2016. https:\/\/doi.org\/10.1155\/2016\/1293649.","journal-title":"Gastroenterol Res Pract"},{"key":"4478_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194352","author":"LW Chen","year":"2021","unstructured":"Chen LW, Chang LC, Hua CC, Liu CJ, Chou TS, Lin CL, et al. The application of high-dose proton pump inhibitor induction treatment before dual therapy for helicobacter pylori eradication: an open-label random trial. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10194352.","journal-title":"J Clin Med"},{"key":"4478_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00482-4","author":"AI Sharara","year":"2002","unstructured":"Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents. 2002. https:\/\/doi.org\/10.1016\/S0924-8579(01)00482-4.","journal-title":"Int J Antimicrob Agents"},{"key":"4478_CR9","doi-asserted-by":"crossref","unstructured":"Hassan M, Noureddine M, Assi F, Houmani Z. Eradication rate of Helicobacter pylori by classic triple therapy in Lebanon: is it still effective? Integr Clin Med. 2018;2(3).","DOI":"10.15761\/ICM.1000129"},{"key":"4478_CR10","doi-asserted-by":"crossref","unstructured":"Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(14).","DOI":"10.3748\/wjg.v21.i14.4345"},{"key":"4478_CR11","doi-asserted-by":"crossref","unstructured":"Ierardi E, Losurdo G, Fortezza RF La, Principi M, Barone M, Leo A Di. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol. 2019;25.","DOI":"10.3748\/wjg.v25.i34.5097"},{"key":"4478_CR12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.3442","author":"L He","year":"2015","unstructured":"He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015. https:\/\/doi.org\/10.2169\/internalmedicine.54.3442.","journal-title":"Intern Med"},{"key":"4478_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz046","author":"WC Tai","year":"2019","unstructured":"Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019. https:\/\/doi.org\/10.1093\/jac\/dkz046.","journal-title":"J Antimicrob Chemother"},{"key":"4478_CR14","doi-asserted-by":"publisher","DOI":"10.1517\/17425250903386251","author":"JC Yang","year":"2010","unstructured":"Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics\/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opinion on Drug Metabolism & Toxicology. 2010. https:\/\/doi.org\/10.1517\/17425250903386251.","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"4478_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.490","author":"T Iwahi","year":"1991","unstructured":"Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991. https:\/\/doi.org\/10.1128\/AAC.35.3.490.","journal-title":"Antimicrob Agents Chemother"},{"key":"4478_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00032.x","author":"J Weil","year":"1991","unstructured":"Weil J, Bell GD, Powell K, Morden A, Harrison G, Gant PW, et al. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther. 1991. https:\/\/doi.org\/10.1111\/j.1365-2036.1991.tb00032.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"4478_CR17","doi-asserted-by":"crossref","unstructured":"Shin J, and NKJ of neurogastroenterology, 2013 undefined. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. synapse.koreamed.orgJM Shin, N KimJournal of neurogastroenterology and motility, 2013\u2022synapse.koreamed.org. 2013;19(1):25\u201335. Available from: https:\/\/synapse.koreamed.org\/upload\/synapsedata\/pdfdata\/0081jnm\/jnm-19-25.pdf. Cited 2025 Oct 23.","DOI":"10.5056\/jnm.2013.19.1.25"},{"key":"4478_CR18","unstructured":"Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, et al. High-dose Rabeprazole\/Amoxicillin therapy as the second-line regimen after failure to Eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, Clarithromycin and Amoxicillin. Hepatogastroenterology. 2003;50(54)."},{"key":"4478_CR19","doi-asserted-by":"crossref","unstructured":"Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015;21(4).","DOI":"10.3748\/wjg.v21.i4.1305"},{"key":"4478_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-12","author":"KR Kulich","year":"2008","unstructured":"Kulich KR, Madisch A, Pacini F, Piqu\u00e9 JM, Regula J, Van Rensburg CJ, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008. https:\/\/doi.org\/10.1186\/1477-7525-6-12.","journal-title":"Health Qual Life Outcomes"},{"key":"4478_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2020.08.014","author":"S Hallit","year":"2021","unstructured":"Hallit S, Haddad C, Sacre H, Rahme C, Akel M, Saleh N, et al. Medication adherence among Lebanese adult patients with hypothyroidism: validation of the Lebanese Medication Adherence Scale and correlates. Clin Epidemiol Glob Health. 2021. https:\/\/doi.org\/10.1016\/j.cegh.2020.08.014.","journal-title":"Clin Epidemiol Glob Health"},{"key":"4478_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00168","author":"Y Hu","year":"2017","unstructured":"Hu Y, Zhu Y, Lu NH. Novel and effective therapeutic regimens for helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017. https:\/\/doi.org\/10.3389\/fcimb.2017.00168.","journal-title":"Front Cell Infect Microbiol"},{"key":"4478_CR23","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.201475","author":"MR Couturier","year":"2014","unstructured":"Couturier MR, Marshall BJ, Goodman KJ, M\u00e9graud F. Helicobacter pylori diagnostics and treatment: could a lack of universal consensus be the best consensus? Clin Chem. 2014. https:\/\/doi.org\/10.1373\/clinchem.2012.201475.","journal-title":"Clin Chem"},{"key":"4478_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x","author":"WD Chey","year":"2007","unstructured":"Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01393.x.","journal-title":"Am J Gastroenterol"},{"key":"4478_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00449-x","author":"E Tshibangu-Kabamba","year":"2021","unstructured":"Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance \u2014 from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021. https:\/\/doi.org\/10.1038\/s41575-021-00449-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4478_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-019-00949-4","author":"SK Jha","year":"2019","unstructured":"Jha SK, Mishra MK, Saharawat K, Jha P, Purkayastha S, Ranjan R. Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: a prospective open-label randomized controlled trial. Indian J Gastroenterol. 2019. https:\/\/doi.org\/10.1007\/s12664-019-00949-4.","journal-title":"Indian J Gastroenterol"},{"key":"4478_CR27","doi-asserted-by":"crossref","unstructured":"Lee HJ, Kim J Il, Lee JS, Jun EJ, Oh JH, Cheung DY, et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol. 2015;21(1).","DOI":"10.3748\/wjg.v21.i1.351"},{"key":"4478_CR28","unstructured":"Zullo A, Ridola L, De Francesco V, Gatta L, Hassan C, Alvaro D, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28(4)."},{"key":"4478_CR29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.111282000.x","author":"L Laine","year":"1996","unstructured":"Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996. https:\/\/doi.org\/10.1046\/j.1365-2036.1996.111282000.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"4478_CR30","doi-asserted-by":"crossref","unstructured":"Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, et al. Antibiotic resistance and therapy outcome in H. Pylori eradication failure patients. Antibiotics. 2020;9(3).","DOI":"10.3390\/jcm9051299"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04478-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:46:39Z","timestamp":1767048399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04478-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4478"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04478-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Notre Dame de Secours. Written informed consent was obtained from all subjects. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"881"}}